Gapping down
In reaction to disappointing earnings/guidance: FTEK -19%, BONT -8% (also announces Brendan L. Hoffman's term as President and Chief Executive Officer will end in 2015), AEO -6.8%, URBN -4.5%, CASY -2.4%, VRNG -2.1%, RNF -1.8% (light volume), SNTA -1.2%(also Synta Pharma and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer), DD -0.9%.
European financial names showing weakness: BCS -3.3%, NBG -2.4%, RBS -2.2%, DB -1.5%, CS -0.8%, HSBC -0.4%.
A few oil/gas related names showing early weakness: CEO -2.6%, RDS.A -1%, BP -0.3%, .
Other news: AMZG -10.9% (announces exercise of purchase option and updated 2014 capital budget; Announces offering of 10 mln shares of common stock after giving effect to a 1 for 4 reverse stock split that will occur concurrently with pricing of the offering), MYGN -9.4% ( request for injunction in patent related dispute has been denied, according to reports), OXLC -3.9% (commences public offering of 2.35 mln shares of common stock), VIPS -3.4% (proposes to offer $400 mln of the Notes due 2019; downgraded to Neutral from Buy at Goldman), ACMP -3.2% (announced the commencement of an underwritten public offering of 8 mln common units representing limited partner interests owned by Global Infrastructure Partners II), STCK -2.3% (announces commencement of public offering of 6.6 mln shares of common stock by selling stockholders), TKMR -2.2% (announced that it is offering to sell shares of its common stock in an underwritten public offering to raise gross proceeds of ~US$60 mln), HLF -1.8% (ahead of Pershing presentation), KO -1.7% (Coca Cola discloses GMCR stake in 13D), MMYT -1.3% (announces public offering of 4.5 mln ordinary shares), NVO -1.2% (still checking), AMGN -1.1% (Amgen and Bayer report Phase 3 Study results of NEXAVAR as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation), CCL -1.1% (still checking), MCD -0.3% (Barron's profiles cautious view on McDonalds), BHP -0.2% ( plans to sell African iron ore assets, according to reports).
Analyst comments: ARTX -1.8% (downgraded to Neutral from Buy at B. Riley & Co. on valuation; tgt raised to $5 from $3.70), NXTM -3.5% ( downgraded to Underperform from Market Perform at Wells Fargo), RKUS -2% (initiated with a Underperform at Bernstein), AIXG -1.9% (downgraded to Neutral from Outperform at Exane BNP Paribas), NTRS -1.3% (downgraded to Sell from Neutral at UBS), ARUN -0.7% (initiated with a Underperform at Bernstein), USB -0.4% (downgraded to Market Perform from Outperform at Keefe Bruyette ), INTC -0.2% (initiated with a Sell at Ascendiant Capital Markets)
European financial names showing weakness: BCS -3.3%, NBG -2.4%, RBS -2.2%, DB -1.5%, CS -0.8%, HSBC -0.4%.
A few oil/gas related names showing early weakness: CEO -2.6%, RDS.A -1%, BP -0.3%, .
Other news: AMZG -10.9% (announces exercise of purchase option and updated 2014 capital budget; Announces offering of 10 mln shares of common stock after giving effect to a 1 for 4 reverse stock split that will occur concurrently with pricing of the offering), MYGN -9.4% ( request for injunction in patent related dispute has been denied, according to reports), OXLC -3.9% (commences public offering of 2.35 mln shares of common stock), VIPS -3.4% (proposes to offer $400 mln of the Notes due 2019; downgraded to Neutral from Buy at Goldman), ACMP -3.2% (announced the commencement of an underwritten public offering of 8 mln common units representing limited partner interests owned by Global Infrastructure Partners II), STCK -2.3% (announces commencement of public offering of 6.6 mln shares of common stock by selling stockholders), TKMR -2.2% (announced that it is offering to sell shares of its common stock in an underwritten public offering to raise gross proceeds of ~US$60 mln), HLF -1.8% (ahead of Pershing presentation), KO -1.7% (Coca Cola discloses GMCR stake in 13D), MMYT -1.3% (announces public offering of 4.5 mln ordinary shares), NVO -1.2% (still checking), AMGN -1.1% (Amgen and Bayer report Phase 3 Study results of NEXAVAR as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation), CCL -1.1% (still checking), MCD -0.3% (Barron's profiles cautious view on McDonalds), BHP -0.2% ( plans to sell African iron ore assets, according to reports).
Analyst comments: ARTX -1.8% (downgraded to Neutral from Buy at B. Riley & Co. on valuation; tgt raised to $5 from $3.70), NXTM -3.5% ( downgraded to Underperform from Market Perform at Wells Fargo), RKUS -2% (initiated with a Underperform at Bernstein), AIXG -1.9% (downgraded to Neutral from Outperform at Exane BNP Paribas), NTRS -1.3% (downgraded to Sell from Neutral at UBS), ARUN -0.7% (initiated with a Underperform at Bernstein), USB -0.4% (downgraded to Market Perform from Outperform at Keefe Bruyette ), INTC -0.2% (initiated with a Sell at Ascendiant Capital Markets)